CIPH Ciphergen Biosystems (MM)

Scientific Advisory Board to Assist in Strategic Management of Diagnostic Pipeline FREMONT, Calif., June 12 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) today announced the establishment of a Scientific Advisory Board to assist in directing the Company's product development strategies. Members of the scientific advisory board are distinguished members of academia and industry with experience in diagnostic test development and commercialization. "With the initiation of our scientific advisory board, Ciphergen has taken another important step towards becoming a leading provider of molecular diagnostic tests based on novel proteomics technologies," said Gail S. Page, President and CEO. "These scientists will meet regularly with our senior management team to help leverage our intellectual property portfolio, guide our resource allocation, and evaluate our ongoing diagnostic programs and prioritize them towards commercialization. Their collective medical research and diagnostic industry experience is extraordinary; these scientists can provide insights that help drive Ciphergen forward into the new era of high value molecular diagnostics." The scientific advisory board is composed of the following individuals: -- Robert C. Bast, Jr., MD, is Vice President for Translational Research and the Harry Carothers Wiess Distinguished University Professor for Cancer Research at the University of Texas M.D. Anderson Cancer Center. Dr. Bast is best known for developing the Ovarian Cancer (OC) 125 monoclonal antibody that led to the production of the CA125 radioimmunoassay. Serum CA125 levels have provided the first generally useful marker for monitoring the course of patients with epithelial ovarian cancer. CA 125 is currently being evaluated as one component of a screening strategy for ovarian cancer. Dr. Bast has published more than 500 articles and chapters, and has edited the textbook Cancer Medicine. He continues to care for patients with breast and ovarian cancer and has been listed in the Best Doctors of America and in America's Top Physicians. Dr. Bast received his B.A. cum laude from Wesleyan University and his M.D. magna cum laude from Harvard Medical School. -- Daniel W. Chan, PhD, DABCC, FACB, is Professor of Pathology, Oncology, Urology and Radiology, Director of Clinical Chemistry Division, Department of Pathology, and the Director, Center for Biomarker Discovery at the Johns Hopkins University School of Medicine. Dr. Chan is an internationally recognized authority in clinical chemistry, proteomics, immunoassay, and biochemical tumor markers (particularly breast and prostate cancer markers). He is particularly well-known as a leader in the concept and methodology of the clinical usefulness of prostate-specific antigen (PSA) as a marker for prostate cancer. He has published over 200 scientific articles, five books on immunoassay automation, endocrinology, and tumor markers. His research has led to major findings showing the importance of analytical methodologies of laboratory testing in diagnosing, managing, and understanding human cancers. He is the Editor-in-Chief of the journal Clinical Proteomics. Dr. Chan received his Ph.D. from the State University of New York at Buffalo -- Ian Jacobs, MD, FRCOG, is Director of the Department of Gynecological Oncology and of the Institute of Women's Health at University College London. Professor Jacobs is recognized as one of Europe's leading academic gynecological oncologists and is President of the European Society of Gynaecological Oncologists. His research includes heading the UK Collaborative Trial of Ovarian Cancer Screening involving 200,000 women in the UK, as well as laboratory studies of the genetic basis of gynecological cancers. Professor Jacobs' clinical activities and expertise include the surgical management of gynecological cancer, management of familial cancer and screening for ovarian and cervical cancer. Professor Jacobs has authored or co-authored more than 200 articles, reviews and chapters. He qualified at Cambridge University and London University before training in clinical medicine and research in Cambridge, at Duke University and at The Royal London, St Bartholomew's and Royal Marsden Hospitals in London. -- Joyce G. Schwartz, MD, is Vice President & Chief Laboratory Officer of Quest Diagnostics. Dr. Schwartz is responsible for medical operations and medical quality for the company's core laboratory testing business. Dr. Schwartz is board-certified in anatomic and clinical pathology, with many years of academic and hospital experience. Prior to joining Quest Diagnostics, Dr. Schwartz held a tenured position as Professor at the University of Texas Health Science Center at San Antonio. She received her BS and MA degrees from the University of Texas at Austin and she received her medical degree from the University of Texas Health Science Center at San Antonio, where she served as Chief Resident in Anatomic and Clinical Pathology. Dr. Schwartz has published over eighty articles in peer-reviewed medical and scientific publications -- William Wallen, PhD, is Senior Vice President and Chief Scientific Officer of Idexx Laboratories, a worldwide leader in innovative products and services for veterinary, food and water applications. Before joining Idexx, Dr. Wallen was Senior Vice President and Head, Office of Technology for the Diagnostics Division of Bayer Healthcare. In his ten years with Bayer, Dr. Wallen held various senior scientific and leadership positions, including as Head of Research and Development for Bayer's laboratory testing and Head of Research for the nucleic acid diagnostics segment. He has authored or co-authored more than 50 scientific papers and articles covering topics in immunology, virology, oncology and detection methodologies. Dr. Wallen earned his bachelor's degree in zoology and his masters in microbiology from Michigan State University and his doctorate in Molecular Biology from the University of Arizona College of Medicine. About Ciphergen Ciphergen is dedicated to translating protein biomarkers and panels of biomarkers into protein molecular diagnostic tests that improve patient care. We are also focused on providing collaborative R&D services through our Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: This press release contains forward-looking statements. For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding Ciphergen's ability to create and commercialize diagnostic tests that are useful in the prevention of disease, and the usefulness of the scientific advisory board in the direction of such efforts. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the risk that Ciphergen may not be able to develop diagnostic tests based on the discoveries of certain biomarkers. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-K filed March 17, 2006, for further information regarding these and other risks related to the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505-2297 Web site: http://www.ciphergen.com/

Copyright